Economic benefits from the use of parecoxib for pain control in adult patients undergoing surgical procedures and renal colic

Abstract

INTRODUCTION: The pain control in the postoperative period is fundamental for allowing control of clinical changes resulting from the painful condition that can lead to increased resource utilization and hospital stay. The development of non-steroidal anti-inflammatory drugs (NSAIDs) cyclooxygenase-2 enzyme inhibitors (COX-2), as the parecoxib, enabled a reduction in the risk of adverse events associated with non-selective NSAIDs, reduction in the consumption of opioids, besides the reduction in the consumption of antacids and antiemetics, in the postoperative period. OBJECTIVES: Assess the cost-effectiveness of the parecoxib in moderate to severe pain in adult patients undergoing surgical procedures. METHODS: Assessing the cost-benefit of the use of parecoxib in the treatment of pain in adult patients undergoing surgical procedures by searching in the studies conducted in different settings and countries and database analyze. RESULTS: The use of parecoxib in pain management proved advantageous when compared to other NSAIDs averaged saving: R$ 30,90 reduction adverse events related, R$ 87,47 synergistic action with opioids, R$ 12,59 reduc[1]tion features (nursing staff and medical supplies) related to pain management, R$ 296,71 reduction inpatient time and R$ 807 in the cost of hospital permanence to renal colic Conclusions: The use of parecoxib results in an effective control of pain, enabling a reduction of complications associated with it and therefore in a higher rate of success of surgery, lowers average length of hospital stay, a significant reduction in resource use and costs.